Nuvalent Inc is a pioneering biopharmaceutical company focused on developing innovative cancer treatments. With a keen eye on addressing the limitations of current therapies, Nuvalent is advancing a portfolio of selective inhibitors designed to combat treatment resistance, minimize adverse events, and tackle brain metastases in cancer patients. Their leading candidates, including NVL-520 for lung cancer and NVL-655 for other cancers, are in clinical trials, showcasing the company's commitment to improving patient outcomes. Founded in 2017 and based in Cambridge, Massachusetts, Nuvalent is at the forefront of targeted cancer therapy research.
Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session,…
Pre-Market Stock Futures: Futures are trading lower after the stock market tried to take a cue from Monday’s action, and things didn’t work out quite as well on Tuesday. Once again, the…
The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names…
